Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2026-03-25 Board/Management Inform…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
CHANGE OF CHIEF EXECUTIVE OFFICER
Board/Management Information Classification · 99% confidence The document is an announcement by Simcere Pharmaceutical Group Limited regarding the appointment of a new Chief Executive Officer and the cessation of the current CEO. It details the biographical profile, appointment effective date, board resolutions, and management decisions. This is a direct change in senior management, fitting the definition of a Board/Management Information filing (MANG).
2026-03-25 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 94% confidence The document is titled “Announcement of Annual Results for the Year Ended December 31, 2025” and contains summarized financial highlights, business highlights, and Management Discussion & Analysis. It is an initial stock exchange announcement of full-year results rather than the complete Annual Report (10-K) with exhaustive notes, nor is it merely a notice of report publication. It provides key performance metrics and commentary in the style of an earnings release. Therefore, it fits the Earnings Release category (ER). FY 2025
2026-03-25 English
FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2025
Notice of Dividend Amount Classification · 95% confidence The document is an official announcement titled “Cash Dividend Announcement for Equity Issuer,” detailing the final dividend amount (RMB 0.18 per share), ex-dividend date, record date, payment date, shareholder approval date, and related share register information. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-03-25 English
VOLUNTARY ANNOUNCEMENT - SIM0237 PHASE I/II CLINICAL STUDY DATA IN NON-MUSCLE-INVASIVE BLADDER CANCER PRESENTED AT THE EUROPEAN ASSOCIATION OF UROLOGY ANNUAL CONGRESS 2026
Regulatory Filings Classification · 98% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding clinical trial data for a drug (SIM0237) presented at a medical congress. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business/R&D development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2026-03-17 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1445 characters) from Simcere Pharmaceutical Group Limited stating that a board meeting will be held on March 25, 2026, to approve the annual results for the year ended December 31, 2025. This is a standard 'Notice of Board Meeting' which serves as an announcement regarding the upcoming publication of a report, rather than the report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-03-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into specific categories like 'Annual Report' or 'Earnings Release' but is a recurring regulatory disclosure. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.